Physician profile
Christopher Walsh
NPI 1174880801
$6,179.67
in general payments reported to CMS, 2019-2025
30 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $299 · 2021: $410 · 2022: $1,409 · 2023: $678 · 2024: $1,214 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $863.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $665.84 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $627.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $570.62 | 2019-2025 | |
| Abbvie INC. | $488.36 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $477.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $303.84 | 2022 | |
| Merck Sharp & Dohme LLC | $244.33 | 2019-2024 | Capvaxive |
| Glaxosmithkline, LLC. | $240.38 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $213.30 | 2022-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $186.21 | 2022-2024 | |
| Allergan, INC. | $162.62 | 2019 | |
| Merit Medical Systems INC | $161.41 | 2024 | Endomaxx Stent and Delivery System |
| Bayer Healthcare Pharmaceuticals INC. | $157.36 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $101.73 | 2020-2024 | Myrbetriq, Veozah |
| Janssen Pharmaceuticals, INC | $93.00 | 2019-2022 | |
| Exact Sciences Corporation | $62.77 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $50.59 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $47.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.08 | 2019 | |
| Dexcom, INC. | $42.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $30.90 | 2019 | |
| Axsome Therapeutics, INC. | $27.52 | 2024 | Auvelity |
| Nevro Corp. | $22.68 | 2019 | |
| Philips North America LLC | $21.29 | 2024 | (Ck6) Holter |
| Regeneron Healthcare Solutions, INC. | $21.18 | 2019 | |
| Abbott Laboratories | $18.55 | 2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $15.03 | 2019 | |
| Zyla Life Sciences, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.